Alta Vista Ventures Ltd. (AVV-CSE) is pleased to announce that it has added Dr. Bob Melamede to its Advisory Board.
Dr. Melamede earned his Ph.D. in Molecular Biochemistry in 1980. In 2013 he retired from University of Colorado at Colorado Springs as a tenured Associate Professor. He is very well known as a leader in the advancement of medical cannabis internationally. He has authored or co-authored numerous scientific papers and articles with his focus being cannabinoids and their effects on illnesses and human health. In 2002, until his retirement, he taught the world's first college level course on Endocannabinoids and Medical Marijuana.
Also in 2013 he retired as CEO from Cannabis Science, a public company that he helped found in 2005. Currently, he is associated with a number of private and public organizations concentrating in the medical marijuana sector. His novel approach regarding the metabolic underpinning of diseases and how they can be manipulated by cannabinoids has many applications for developing cannabis-based treatments for numerous illnesses.
By joining Alta Vista's Advisory Board Dr. Melamede will bring his industry knowledge and contacts to the Company.
About Alta Vista Ventures:
Alta Vista Ventures has signed a Letter of Intent to purchase Thor Pharma Ltd. Thor Pharma is based in Burlington Ontario and has an MMPR (Marijuana for Medical Purposes Regulations) application with Heath Canada that is in the Detailed Security Clearance stage of the application process. To view a video of the facility to be used by Thor Pharma please visit www.medicalmarihuana.net.
Investors are cautioned that the purchase of Thor Pharma remains subject to due diligence and the signing of a definitive agreement. Alta Vista cannot guarantee nor estimate the timing for the issuance of an MMPR license to Thor Pharma.
On behalf of the Board,
"Ian Foreman"
Ian Foreman
President
For information on Thor Pharma please contact Mr. Don Shaxon at 289-838-5938.
For additional information on Alta Vista Ventures please call the Company at 604-678-2531.
Neither Canadian Securities Exchange (CSE) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Statements in this press release, other than purely historical information, including statements relating to the Company's future plans and objectives or expected results, may include forward-looking statements. Forward-looking statements are based on numerous assumptions and are subject to all of the risks and uncertainties inherent in resource exploration and development. As a result, actual results may vary materially from those described in the forward-looking statements.
